Satsuma Pharmaceuticals, a subsidiary of Shin Nippon Biomedical Laboratories (TYO:2395), has secured US FDA approval for Atzumi (dihydroergotamine nasal powder) to treat acute migraines in adults, according to a Thursday filing on the Tokyo Stock Exchange.
Developed using Shin Nippon Biomedical's unique intranasal delivery platform, Atzumi is the first FDA-approved nasal migraine treatment. The approval follows successful Phase 1 and Phase 3 trials.
Price (JPY): $1562.00, Change: $-3.0, Percent Change: -0.19%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。